References
- Lawn W, Hallak JE, Crippa JA, et al. Well-being, problematic alcohol consumption and acute subjective drug effects in past-year ayahuasca users: a large, international, self-selecting online survey. Sci Rep. 2017;7:1–10.
- Regester LE, Chmiel JD, Holler JM, et al. Determination of designer drug cross-reactivity on five commercial immunoassay screening kits. J Anal Toxicol. 2015;39:144–151.
- Jiang XL, Shen HW, Mager DE, et al. Pharmacokinetic interactions between monoamine oxidase A inhibitor harmaline and 5-methoxy-N,N-dimethyltryptamine, and the impact of CYP2D6 status. Drug Metabol Dispos. 2013;41:975–986.
- Bilhimer MH, Schult RF, Higgs KV, et al. Acute Intoxication following dimethyltryptamine ingestion. Case Rep Emerg Med. 2018;2018:1.
- Sklerov J, Levine B, Moore KA, et al. A fatal intoxication following the ingestion of 5-methoxy-N,N-dimethyltryptamine in an ayahuasca preparation. J Anal Toxicol. 2005;29:838–841.
- Riba J, McIlhenny EH, Valle M, et al. Metabolism and disposition of N,N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca. Drug Test Anal. 2012;4:610–616.